A few additional thoughts on this topic.
TaiMed's product is also for a substantially smaller patient population size -- MDR 3 vs. our MDR 2; where MDR 3 is stated by their company to be 12-15k patients a year in the US.
TM also received approval more quickly, with the use of less capital, and without the roadmap to approval that they provided to us.
14.5 times more dilution than a directly comparable company should make any long term shareholder upset with management.
LERO is proving to be more than it was even billed for, and hopefully management can get out of the product's way by closing the licensing deal and filing the BLA asap.
And then, if we are really lucky, a new management team can come in and take us to the big board. I don't think even the most ardent supporters of NP think he is ready for being the face of the company on the big board and communication conduit to the analysts.
That would give NP a graceful exit and line his pocketbook much better than him fumbling through trying to learn how to play the game with the Street (something that takes a career to learn and some innate abilities).
News 
Market Data 
Discover 
